Zacks Research Has Bullish Outlook for Revvity Q2 Earnings

Revvity, Inc. (NYSE:RVTY) – Zacks Research lifted their Q2 2025 earnings per share (EPS) estimates for shares of Revvity in a report issued on Monday, November 25th. Zacks Research analyst R. Department now expects that the company will post earnings per share of $1.28 for the quarter, up from their previous estimate of $1.27. The consensus estimate for Revvity’s current full-year earnings is $4.85 per share. Zacks Research also issued estimates for Revvity’s FY2025 earnings at $5.17 EPS, Q2 2026 earnings at $1.40 EPS and FY2026 earnings at $5.67 EPS.

Revvity (NYSE:RVTY) last posted its earnings results on Monday, November 4th. The company reported $1.28 EPS for the quarter, topping analysts’ consensus estimates of $1.13 by $0.15. The business had revenue of $684.10 million during the quarter, compared to the consensus estimate of $679.66 million. Revvity had a net margin of 9.34% and a return on equity of 7.42%. The firm’s revenue was up 2.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.18 EPS.

Other analysts have also recently issued research reports about the company. Wells Fargo & Company started coverage on Revvity in a research report on Tuesday, August 27th. They issued an “equal weight” rating and a $130.00 price target for the company. Raymond James increased their target price on shares of Revvity from $144.00 to $146.00 and gave the stock an “outperform” rating in a report on Tuesday, November 5th. TD Cowen lifted their price target on shares of Revvity from $141.00 to $144.00 and gave the company a “buy” rating in a report on Tuesday, November 5th. Robert W. Baird increased their price objective on shares of Revvity from $136.00 to $138.00 and gave the stock an “outperform” rating in a research note on Tuesday, November 5th. Finally, Barclays lowered their target price on shares of Revvity from $140.00 to $135.00 and set an “overweight” rating on the stock in a research note on Monday. Seven research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $131.73.

Revvity Price Performance

Shares of NYSE:RVTY opened at $116.23 on Thursday. The firm’s 50 day moving average price is $119.84 and its 200-day moving average price is $115.89. The company has a quick ratio of 2.97, a current ratio of 3.56 and a debt-to-equity ratio of 0.40. The stock has a market capitalization of $14.15 billion, a PE ratio of 56.15, a price-to-earnings-growth ratio of 2.86 and a beta of 1.05. Revvity has a twelve month low of $86.30 and a twelve month high of $129.50.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the business. Rothschild Investment LLC acquired a new position in shares of Revvity in the 2nd quarter valued at $25,000. Gladius Capital Management LP purchased a new position in Revvity during the 3rd quarter worth $32,000. Continuum Advisory LLC increased its stake in Revvity by 2,972.7% in the third quarter. Continuum Advisory LLC now owns 338 shares of the company’s stock valued at $43,000 after purchasing an additional 327 shares during the period. EverSource Wealth Advisors LLC raised its holdings in shares of Revvity by 74.2% in the second quarter. EverSource Wealth Advisors LLC now owns 392 shares of the company’s stock valued at $41,000 after buying an additional 167 shares during the last quarter. Finally, Avior Wealth Management LLC boosted its stake in shares of Revvity by 7,980.0% during the third quarter. Avior Wealth Management LLC now owns 404 shares of the company’s stock worth $52,000 after buying an additional 399 shares during the period. 86.65% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Revvity news, insider Tajinder S. Vohra sold 2,154 shares of the stock in a transaction that occurred on Wednesday, October 9th. The shares were sold at an average price of $121.73, for a total transaction of $262,206.42. Following the sale, the insider now directly owns 19,652 shares in the company, valued at $2,392,237.96. This represents a 9.88 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 0.60% of the stock is currently owned by corporate insiders.

Revvity declared that its Board of Directors has authorized a stock repurchase plan on Monday, November 4th that authorizes the company to repurchase $1.00 billion in outstanding shares. This repurchase authorization authorizes the company to purchase up to 6.5% of its stock through open market purchases. Stock repurchase plans are often a sign that the company’s management believes its stock is undervalued.

Revvity Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, February 7th. Investors of record on Friday, January 17th will be given a dividend of $0.07 per share. The ex-dividend date is Friday, January 17th. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.24%. Revvity’s payout ratio is currently 13.53%.

About Revvity

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.